

# Medical Section Annual Meeting

Jointly Provided by



February 18–21, 2017

RITZ-CARLTON, NEW ORLEANS  
NEW ORLEANS, LA

## SATURDAY, FEBRUARY 18

- 3:00–5:00 PM **REGISTRATION** – *Crescent View Foyer – 12<sup>th</sup> floor*
- 3:00–4:00 PM **MEMBERSHIP AND MEDICAL RELATIONS COMMITTEE** – *Crescent View – 12<sup>th</sup> floor*
- 4:00–5:00 PM **BOARD OF MANAGERS MEETING** – *Crescent View – 12<sup>th</sup> floor*
- 6:00–6:30 PM **FIRST-TIME ATTENDEE RECEPTION** – *Mercier Terrace & Courtyard – 14<sup>th</sup> floor*
- 6:30–7:30 PM **RECEPTION IN HONOR OF MEDICAL SECTION CHAIR ROSALIE MASTROPOLO**– *Mercier Terrace & Courtyard – 14<sup>th</sup> floor*
- 7:30 PM **BOARD OF MANAGERS DINNER** (by invite only)

## SUNDAY, FEBRUARY 19

- 7:15 AM–1:00 PM **REGISTRATION** – *Audubon Foyer*
- 7:15–8:15 AM **BREAKFAST** – *Audubon*
- 8:15 AM–1:15 PM **SCIENTIFIC SESSIONS** – *Audubon*
- 8:15–8:30 AM **OPENING REMARKS**  
*Rosalie Mastropolo, ACLI Medical Section Chair*
- 8:30–9:30 AM **EMERGENCE OF MULTI-DRUG RESISTANT ORGANISMS**  
*David Mushatt, MD, MPH & TM*
- 9:30–10:30 AM **MCI/ALZHEIMER'S**  
*Roger E. Kelley, MD*
- 10:30–10:45 AM **REFRESHMENT BREAK** – *Audubon Foyer*
- 10:45–11:45 AM **RARE GI MALIGNANCIES**  
*Jordan Karlitz, MD*

11:45 AM–1:15 PM **MEDICAL ISSUES COMMITTEE**

**TRANSGENDER PANEL**

*Sue Ellen Abdalian, MD*

*Jamie Buth, MD*

**ACLI LEGISLATIVE UPDATE**

*Mariana Gomez-Vock, ACLI*

*Bill Ray, State Farm, M.I.C. Chair*

1:15 PM **AFTERNOON FREE/DINNER ON YOUR OWN**

**MONDAY, FEBRUARY 20**

7:15 AM–4:45 PM **REGISTRATION** – Audubon Foyer

7:15–8:30 AM **BREAKFAST SESSION – “STEM CELLS, PRACTICAL AND POTENTIAL USES AND ABUSES”**– Algiers

*Bruce A. Bunnell, Ph.D.*

8:30–4:45 PM **SCIENTIFIC SESSIONS** – Audubon

8:30–9:30 AM **BNP AS A PREDICTOR OF CV AND ALL-CAUSE MORTALITY**

*Thierry H. Le Jemtel, MD*

9:30–10:30 AM **BARRETT'S**

*John Affronti, MD*

10:30–10:45 AM **REFRESHMENT BREAK** – Audubon Foyer

10:45–11:45 AM **NEWER MARKERS OF CAD**

*Robert Hendel, MD*

12:00–1:30 PM **LUNCH/BUSINESS SECTION MEETING** – Algiers

1:30–2:30 PM **PRESCRIPTION DRUG ABUSE**

*Mordecai N. Potash, MD*

2:30–3:30 PM **HEMATOPOETIC CELL TRANSPLANTATION**

*Hana Safah, MD*

3:30–3:45 PM **REFRESHMENT BREAK** – Audubon Foyer

3:45–4:45 PM **TARGETED ONCOLOGIC THERAPIES/PERSONALIZED MEDICINE**

*Reinhold Munker, MD*

6:00 PM **MARDI GRAS RECEPTION/DINNER** – French Quarter Bar

**TUESDAY, FEBRUARY 21**

7:00–11:15 AM **REGISTRATION** – Audubon Foyer

7:00–8:00 AM **BREAKFAST** – Audubon

8:00– 11:15 AM **SCIENTIFIC SESSIONS** – Audubon

8:00–9:00 AM	<b>CHRONIC LEUKEMIAS</b>  <i>Marc J. Kahn, MD, MBA</i>
9:00–10:00 AM	<b>HEPATITIS C</b>  <i>Luis A Balart, MD</i>
10:00–10:15 AM	<b>REFRESHMENT BREAK</b> – Audubon Foyer
10:15–11:15 AM	<b>PEDIATRIC MALIGNANCY: LONG-TERM SURVIVAL AND FOLLOW UP INTO ADULthood</b>  <i>Tammueella Singleton, MD</i>
11:15 AM	<b>CONCLUDE</b>

**ACLI Antitrust Notice**

The American Council of Life Insurers is committed to adhering strictly to the letter and spirit of the antitrust laws. Meetings conducted under ACLI's auspices are designated solely to provide a forum for the expression of the various points of view on topics described in the agenda. Under no circumstances shall ACLI meetings be used as a means for competing companies to reach any understanding, expressed or implied, which tends to restrict competition, or in any way, to impair the ability of members to exercise independent business judgment regarding matters affecting competition.

**STATEMENT OF NEED**

Life and Disability Insurance Medical Directors require current and up to date medical information in order to assess risks accurately and appropriately. Review of current morbidity and mortality data is crucial in order to better serve the insurance industry and the insurance buying public. This scientific activity is designed for the medical officers of legal reserve life insurance companies who assist ACLI in identifying medical/scientific topics and issues of concern to life insurance medicine and its relationship to the underwriting and claims process. These physicians represent a wide range of expertise and day-to-day exposure to current medical issues. The primary purpose is to keep medical officers abreast of state-of-the-art clinical information on pertinent subjects.

**TARGET AUDIENCE:** Physicians, Nurses, Insurance Administrators, Insurance Underwriters

**LEARNER OBJECTIVES**

At the conclusion of this activity, participants should be better able to effectively...

- Identify the risks for the US population in 2017-2018.
- Determine which advancements in clinical medicine will impact the insurance industry.
- Evaluate complex medical data in combination with state-of-the-art clinical information.
- Critically evaluate emerging evidence-based practice which impacts medical underwriting.
- Identify the current and most important population trends in mortality and morbidity risk assessment.
- Evaluate the expected and actual mortality, morbidity, and the benefits and risks of medical intervention related to disease states.

**ACCREDITATION**

This activity has been planned and implemented in accordance with the accreditation policies and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Tulane University Health Sciences Center and American Council of Life Insurers. Tulane University Health Sciences Center is accredited by the ACCME to provide continuing medical education for physicians.

**DESIGNATION**

Tulane University Health Sciences Center designates this live activity for a maximum of 14.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**DISCLOSURE**

It is the policy of the Center for Continuing Education at Tulane University Health Sciences Center to plan and implement all of its educational activities in accordance with the ACCME's accreditation policies and policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME's Standards for Commercial Support, everyone who is in a position to control the content of an educational activity certified for *AMA PRA Category 1 Credit*<sup>™</sup> is required to disclose all financial relationships with any commercial interests within the past 12 months that creates a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity. Individuals with potential for influence or control of CME content include planners and planning committee members, authors, teachers, educational activity directors, educational partners, and others who participate, e.g. facilitators and moderators. This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience.

The Center for Continuing Education has also required that all faculty disclose their intent to discuss any unlabeled/ unapproved usage of drugs and/or devices during their presentations. No one has disclosed that off-label discussions will be included in the presentations.

As of 2/10/17